Table 1.
Patient population and treatment results.
| 1* | 2 | 3* | 4* | 5 | |
|---|---|---|---|---|---|
| Histology | ATC | ATC | ATC with aPTC | ATC | ATC |
| Age at diagnosis (y) | 75 | 62 | 79 | 78 | 63 |
| Gender | Male | Male | Female | Male | Male |
| Stage | M | M | M | LR | LR |
| Prior treatment | None | Carboplatin and paclitaxel with radiation | RAI and thyroidectomyc | None | Carboplatin and paclitaxel with radiation |
| Mutationsa | N/A | N/A | PIK3CAE542K | BRAFV600E | N/A |
| PIK3CAE970K | |||||
| BRAFV600E | |||||
| Duration prescribed everolimus (mo) | 0.8 | 1.7b | 29.5 | 5.3d | 5.9 |
| Best radiologic response, length (mo) | PD | MR | PR, 27.9 | SD, 3.7 | SD, 5.9 |
| Overall survival (mo) | D, 0.8 | D, 2.8 | D, 39.2 | D, 7.4 | D, 16.5 |
*
First-line of treatment
a
only actionable mutations included,
b
EMR did not capture patient's final month alive, was not included in analysis,
c
Treatment for PTC, prior to ATC diagnosis,
d
Continued everolimus after radiologic PD, aPTC, associated component of papillary thyroid carcinoma; M, metastatic; LR, locoregional; RAI, radioactive iodine; PD, progressive disease; MR, mixed response; PR, partial response; SD, stable disease; D, deceased.